Wee1 kinase participates in the G2-M checkpoint to prevent mitosis in the presence of DNA damage and therefore may play an important role in drug resistance to DNA alkylating agents, by allowing tumor cells to repair DNA damage prior to mitosis. Inhibition of the Wee1 kinase is known to potentiate the effect of chemotherapy in a variety of tumor types. CU researchers have discovered a number of potent Wee1 kinase inhibitors for the treatment of Glioblastoma Multiforme, along with other cancer types. They believe their compounds have improved blood brain barrier penetration and reduced myelosuppression compared to existing Wee1 inhibitor AZD1775.